RXi Pharmaceuticals Corporation has announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.
RXI-109 has been shown to effectively silence a key regulator of scarring, connective tissue growth factor (CTGF), in vitro in cell culture and in vivo in rodent skin models.
After completion of the necessary toxicological studies and clearance of their IND submission by the US Food and Drug Administration, they have now successfully dosed their first subject in a dose escalation study.
“This is an exciting time for RXi Pharmaceuticals, and for RNAi technology in general,” said Pamela Pavco, Chief Development Officer for the company.
“After an intense period of preparation, we are happy to announce the achievement of this significant milestone by RXi.”
She added that “Thanks to the potential of our proprietary self-delivering technology, we believe that RXI-109 will provide a highly selective and efficacious solution to an important unmet medical need. RXI-109 is designed to reduce or prevent skin scarring following trauma or surgery and is intended to reduce disfiguring hypertrophic scarring and keloids.”
RXi’s Phase 1 clinical trial is a dose escalation study designed to evaluate safety and tolerability of RXI-109 in humans and may provide preliminary evidence of the reduction of surgical scars.